HBL Hadasit Bio Holdings

What is HBL Hadasit Bio Holdings?

Hadasit Bio-Holdings Ltd. (HBL) is an investment fund prominently featured on the Tel Aviv Stock Exchange under the ticker HDST and on the OTCBB under the ticker HADSY, which permits public investment in the domain of biotechnology.

The fund represents a pioneering effort in biotech financing, as it enables public participation in a holding entity that encompasses a selection of companies cultivated from the intellectual property generated by one of Israel's leading medical research institutions, the Hadassah University Hospital (HU).

HBL stands as a publicly traded subsidiary of Hadasit Ltd., functioning as the technology transfer organization of the Hadassah University Hospital in Jerusalem.

With the primary aim to advance and capitalize on the intellectual property and R&D prowess originating from Hadassah, HBL drives efforts to bring forth solutions tackling contemporary medical challenges. HBL is known for its holdings in an exclusive portfolio of biotech companies spanning various therapeutic areas, such as Immuno-Oncology, Ophthalmology, and Inflammatory Diseases, where its investments range from partial to minority stakes.

The strategic approach of HBL involves distributing both risk and potential success among multiple companies owing to its public offering structure, which serves to mitigate the inherent risky nature of investment in early-stage biotech ventures.

Their portfolio includes companies such as KAHR Medical, which is revolutionizing cancer treatment through immune-recruiting therapies; Enlivex Therapeutics, a trailblazer in off-the-shelf, universal, macrophage reprogramming cell therapies; and Cell Cure Neurosciences Ltd., a pioneer in harnessing human embryonic stem cells for treating ocular disorders.

HBL's investment strategy emphasizes a robust risk-reward ratio, leveraging economies of scale and integrating a solid foundation based on Hadassah University Hospital's infrastructure. With an experienced management team and a framework that champions the confluence of science, medicine, academia, and business, HBL presents a unique investment vehicle that balances liquidity with the prospects of generating substantive value through exit events.